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Cannabinoid receptors 1 (CB1) and/or 2 (CB2) are overexpressed in many types of human malignancies including mantle cell
lymphoma (MCL). Agonists to CB1 and CB2 promote ceramide de novo synthesis, p38–mitogen-activated protein kinase-
dependentactivationofcaspase-3andapoptoticcelldeathinmostMCLs.However,inthisreportwedescribethatinsomeMCLs
the response to treatment with cannabinoids decreased cell viability as assessed by metabolic activity but did not involve the
caspase-3 cascade or loss of plasma membrane integrity. Both primary cells from one MCL patient and the MCL cell line
Granta519 respondedto treatment with cannabinoids by formation of cycloheximide-sensitive cytoplasmic vacuoles,but did not
enter apoptosis. The persistent expression of mammalian homolog of Atg8 with microtubule-associated protein-1 light chain-3 II
(LC3 II) and p62, as well as the lack of protection from chloroquine, indicates that lysosomal degradation is not involved in this
cytoplasmic vacuolation process, distinguishing from classical autophagy. Transmission electron microscopy images and
immunoﬂuorescence staining of endoplasmic reticulum (ER) chaperone calreticulin showed that the vacuoles were of ER origin
and that chromatin remained normal. These features resemble paraptosis-like cell death—a third type of a programmed
cell death not previously described in response to cannabinoids.
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Mantle cell lymphoma (MCL) is a non-Hodgkin lymphoma of
B-cell type, with a median survival of 3–5 years.
1 Improved
treatment protocols have been presented,
2,3 and patients
below 65 years of age may beneﬁt from intense treatment and
autologous stem cell transplantation. However, the vast
majority of patients cannot be rescued and new treatment
options are clearly needed, therefore search for new therapy
targets is ongoing.
Previously, we have found that MCL has high expression of
the G-protein-coupled receptors, cannabinoid receptors type
1 (CB1) and type 2 (CB2).
4,5 The high expression of CB1 on
lymphoma cells was unexpected, as CB1 is expressed at very
low levels in the immune system.
6,7 CB2 is expressed
on normal B cells, but expression levels are even higher on
the malignant B cells in MCL.
4,5 CB2 may also be highly
expressed in T-cell malignancies.
8,9 In the immune system,
CB2 regulates cell-mediated and humoral immunity
10–12 and
leukocyte migration.
11,13–15
Initially, cannabinoids were used in palliative cancer
therapy. Recently, it has been recognized that cannabinoids
also have speciﬁc anti-tumor activity by inducing selective
cell death in many types of cancer cells but not in the normal
counterparts.
16–18 Our earlier studies demonstrated that
targeting CB1 and CB2 receptors on MCL cell lines and
primary tumors cells with endocannabinoids or other agonists
to cannabinoid receptors (methanandamide and WIN55,
212-2) selectively reduced proliferation and induced de novo
synthesis of ceramides, followed by p38–mitogen-activated
protein kinase (MAPK)-dependent apoptosis of lymphoma
cells.
19,20 Furthermore, the cannabinoid methanandamide
reduced tumor growth in MCL in a xenograft mouse model.
4
Intriguingly, high expression of cannabinoid receptors did
not always result in caspase-3-mediated cell death in
B-cell lymphomas treated with cannabinoids
4 but still, as we
show in the current study, decreased the mitochondrial
activity. We therefore hypothesized that cannabinoids may
induce other types of programmed cell death (PCD) than
apoptosis (PCD I). Here, we show that cannabinoids may
induce non-apoptotic PCD in MCL, widening their therapeutic
potential.
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Cannabinoid-mediated cell death of primary MCL cells
and MCL cell lines. Primary MCL lymphoma cells were
obtained from six patients. From two patients – PA and PB –
two different tissues were obtained. The expression levels of
gene encoding cannabinoid receptor 1 (CNR1) and
cannabinoid receptor 2 (CNR2) was determined by
quantitative PCR (Table 1). The expression levels of the
cannabinoid receptors were normalized to B cells puriﬁed
from a buffy coat from a healthy donor. The effect of the
synthetic cannabinoid WIN55,212-2, a potent agonist to CB1
and CB2 receptors, on cell viability was assessed by two
principally different methods. The integrity of the plasma cell
membrane was analyzed by ﬂow cytometry for the uptake of
the DNA stain propidium iodide (PI), which cannot pass
through intact cell membranes. In addition the XTT viability
assay, which is based on detecting mitochondrial activity,
was used for viability assessment. In ﬁve out of six primary
MCLs, WIN55,212-2 induced a dose-dependent decreased
cell viability, as assessed by ﬂow cytometry, at 48h. Half
maximal inhibitory concentration (IC50) values represent
WIN55,212-2 concentrations at which the viability reaches
50%. These values were varying between B1.5 and 5mM for
PA, PC, PD, PE and PF primary samples. Lymphoma cells
isolated from blood or bone marrow from the patient PB (PB1
and PB2, respectively) were resistant to cannabinoid-
induced PI uptake (Figure 1a). Using the same viability
assay, the Granta519 cell line, but not other MCL cell lines
tested (Rec1, JeKo and JVM2), showed a similar resistance
to WIN55,212-2-induced PI uptake (Figure 1b). In contrast,
using the XTT viability assay, no such difference between
Granta519 and the other MCL cell lines was observed
(Figure 1c). This discordance in viability assessment results
might indicate that different modes of cannabinoid-mediated
toxicity are operational.
Granta519 and PB1 cells are resistant to cannabinoid-
induced apoptosis. We have further analyzed the possible
role of caspase-3-dependent effector mechanism as a
factor underlying the observed differences in cell death.
The response of Granta519 was compared with the other
MCL cell lines, Rec1, JeKo and JVM2 to incubation with
10mM WIN55,212-2 (Figure 2a) or 10mM anandamide (AEA,
N-arachidonoylethanolamine; Figure 2b). At 24h after adding
cannabinoids, all cell lines but Granta519 were dead. Kinetic
studies for up to 10h, using western blot, showed that
after 5h cannabinoids had activated caspase-3 and poly
(ADP-ribose) polymerase (PARP) cleavage in Rec1, JeKo
and JVM2 but not in Granta519 (Figures 2a and b). Similarly,
PARP cleavage was not detected in PB1 cells after treatment
with 10mM WIN55,212-2 (Figure 2c). These data indicate
that Granta519 cells respond to cannabinoids by decreased
metabolic activity, and together with PB1 cells are resistant to
apoptosis.
Phase-contrast microscopy of Granta519 cell cultures
for 48h in the presence of 10mM WIN55,212-2 showed
cytoplasmic vacuoles (Figure 3a). Vacuolation is a feature of
autophagy, but can also be a feature of other processes
such as paraptosis/cytoplasmic vacuolation. In autophagy,
autophagosomes are formed, which ﬁnally fuse to lyso-
somes forming autolysosomes. The process also involves
the conversion of mammalian homolog of Atg8 with
microtubule-associated protein-1 light chain-3 I (LC3 I) to a
PE-conjugated form, denoted LC3 II, which localizes in the
autophagosomes. The formation of LC3 II is, however, not
speciﬁc for autophagy but also occurs during cytoplasmic
vacuolation.
21 We investigated the changes in LC3 I and LC3
II expression levels in MCL cell lines up to 10h of treatment
with 10mM WIN55,212-2. During this time, we did not observe
any enhanced expression of LC3 II in any of MCL cell lines
investigated (Figures 2a and b). However, after incubating
Granta519 cells with 10mM WIN55,212-2 or AEA for 24 and
48h, LC3 II levels were elevated compared with vehicle-
treated cells (Figure 3b).
Cannabinoid-induced vacuolation does not involve
lysosomal degradation and is insensitive to MEK-1 and
-2 inhibitors. During autophagy, the protein p62 localizes in
the autophagosomes and is, together with LC3 II, degraded
in autolysosomes. Therefore, changes in levels of LC3 II and
p62 proteins may reﬂect stages of the autophagy.
22
To characterize the cannabinoid-induced LC3 II-positive
vacuolation, cells were treated with WIN55,212-2 or AEA for
24 and 48h, and levels of the vacuolar membrane protein
p62
22,23 were analyzed. Cannabinoid treatment induced
Table 1 Characteristics of primary samples from patients with MCL and the expression levels of CNR1 and CNR2 in primary MCL cells and in MCL cell lines
Sample Sex Age
(years)
Tissue Purity
(%)
CNR1 CNR2
PA1 M 82 Blood 86 11.25±1.12 4.17±0.18
PA2 Pleural exudate 95 10.83±1.08 2.44±0.14
PB1 F 77 Blood 89 1.16±0.10 2.54±0.26
PB2 Bone marrow 92 6.15±0.77 1.71±0.16
PC M 69 Spleen 80 1.54±0.09 1.79±0.10
PD M 73 Spleen 88 3.27±0.27 1.28±0.02
PE M 77 Lymph node 85 2.33±0.22 1.72±0.12
PF M 66 Blood 69 0.15±0.03 1.17±0.25
Granta519 Blood 1.31±0.09 0.31±0.05
Rec1 Lymph node or blood 2.24±0.52 1.48±0.29
JeKo Blood 1.67±0.47 1.33±0.21
JVM2 Blood 0.00±0.00 0.02±0.00
Thepurityindicates thepercentageoflymphomacellsamongmononuclear cellsevaluated byﬂowcytometry.ThemRNAlevelsweremeasuredusingreal-timePCR.
The CNR1 and CNR2 mRNA levels were normalized to CNR1 and CNR2 mRNA levels in B cells from a buffy coat from a healthy donor, n¼9–12
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Cell Death and Diseasepersistentexpression of LC3 II and did not inﬂuence the levels
of p62 (Figure 3b). The fact that LC3 II and p62 levels did not
decreaseovertimesuggeststhatvacuoleswerenotefﬁciently
fused with the lysosomes. These ﬁndings suggest that the
autophagocytic process was not completed, whereas the
cellular metabolism, measured by XTT, was reduced as
shown in Figure 1c.
To further analyze the vacuoles, we investigated whether
changes in the lysosomal pH by chloroquine (CQ) treatment
would inﬂuence the observed effect of cannabinoids.
However, the cannabinoid-induced reduction of metabolism
was not affected by CQ treatment, indicating that lysosomal
degradation was not involved in the process induced by
cannabinoids (Figure 3c).
Other reports suggest involvement of the MAP/ERK
kinase (MEK)-1/-2 pathway in vacuolation.
21,24 Therefore,
we investigated whether speciﬁc inhibitors of MEK-1 and -2
inﬂuenced the fate of Granta519 cells treated with
WIN55,212-2. However, the MEK-1- and -2-speciﬁc inhi-
bitors, PD98059 and U0126, respectively, were ineffective
in protecting from cell death (Figure 3d).
Cannabinoid-mediated decrease of Granta519 cell
viability occurs in a cannabinoid receptor-independent
manner and requires active protein synthesis. To verify
whether the decrease in Granta519 viability is mediated
via CB1 and CB2, we pretreated cells with SR141716
and SR144528, selective antagonists for CB1 and CB2,
respectively. Cells were pretreated with 10 or 100nM of
SR141716 and SR144528 for 30min and then treated with a
range of concentrations of WIN55,212-2. Neither SR141716,
SR144528 nor a combination of both antagonists inhibited
WIN55,212-2-induced cell death or LC3 II lipidation (Figures
4a and b). Altogether, these ﬁndings suggest that the
cannabinoid-mediated decrease in Granta519 viability
and LC3 II-positive vacuolation are not mediated by CB1
and/or CB2 activation.
Figure 1 Primary MCL cells and cell lines respond differently to WIN55,212-2 treatment. Primary MCL cells (a) and MCL cell lines (b) were treated with WIN55,212-2.
Cell viability was assessed by PI staining at 48h; the WIN55,212-2 concentration at which cell viability reaches 50% (IC50 values) are based on a four-parameter iterative
ﬁtting; (c) XTT assay (n¼3 3) of MCL cell lines: Granta519, Rec1, JeKo and JVM2 treated with WIN55,212-2 for 48h
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Cell Death and DiseaseTo study whether the cannabinoid-induced cell death is
reversible after washing cells off WIN55,212-2, we incubated
Granta519andRec1cellswith10mMWIN55,212-2for3or6h
before washing off the drug. The cells were then cultured for
another 48h. Our results show that the decrease in metabolic
activity, measured by XTT, was signiﬁcantly reversed by
removing the drug both in Granta519 and Rec1 cells
(Figure 5a). For Granta519 cells, washing off the drug also
diminished LC3 II positivity (Figure 5a). We then studied the
effect of longer exposure of WIN55,212-2 on Granta519 cells.
For this, we cultured Granta519 with WIN55,212-2 for 24h,
then washed cells and recultured for another 24h. Then the
decrease in metabolic activity could be signiﬁcantly reversed
(Figure 5b).
We further studied whether the decrease in cell viability
and induction of vacuolation require active protein synthesis.
For this, we blocked the biosynthesis of new proteins with
cycloheximide (CHX) and then treated Granta519 cells with
WIN55,212-2. The addition of CHX signiﬁcantly protected
cells from WIN55,212-2-induced cell death (Figure 5c),
implying the requirement of protein biosynthesis.
Vacuoles in cannabinoid-treated Granta519 cells are of
ER origin. Light and transmission electron microscopy
(TEM) analysis of Granta519 cells at different time points
after treatment with 10mM WIN55,212-2 was used to further
characterize the vacuole formation. Cells incubated with
WIN55,212-2 for 24h showed large cytoplasmic vacuoles,
whereas the plasma membrane was unaffected. We also
observed that the nuclei were intact and noted the occasional
appearance of mitotic ﬁgures (Figure 6a), whereas vehicle-
treated Granta519 cells retained a normal ultrastructural
Figure 2 MCL cell lines have variable response to WIN55,212-2 and AEA. MCL cell lines were incubated with cannabinoids and harvested at different time points.
After 5h, 10mM WIN55,212-2 (a)o r1 0mM AEA (b) causes PARP cleavage (full length¼113kDa, cleaved form¼89kDa) and caspase-3 cleavage (19kDa and 17kDa) in
Rec1,JeKoandJVM2cells,butnotinGranta519cells.CannabinoidsdidnotaffectlevelsofLC3IIinMCLcelllinesupto10hofincubation,n¼2;b-actinorAktwereusedas
a loading control. (c) Expression of PARP in patient PB1 cells treated with 10mM WIN55,212-2 for 24h
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Cell Death and Diseasemorphology, with well deﬁned nuclei containing uniformly
distributed chromatin and well preserved organelles (Figures
6bi and ii). In Granta519 cells treated with 10mM WIN55,
212-2, small amounts of vacuoles in the cytoplasm were
seen already at 2h of incubation, which increased in number
and size with time (Figures 6biii–viii). The vacuoles were
surrounded by membranes and some of these membranes
were decorated by ribosomes (Figure 6biv), indicating that
the intracellular vacuoles were derived from the rough
endoplasmic reticulum (ER) and possibly also smooth ER.
Most mitochondria remained unchanged up to 6–12h of
WIN55,212-2 treatment. Then, we observed dilation of
the cristae membranes and denser mitochondria matrix.
However, in some cells the mitochondrial morphology
remained normal even after 24h of treatment.
The nuclear membrane was also affected, displaying a
widening of the membrane space but with intact nuclear pore
complexes (Figure 6bvi). Notably, the outer plasma mem-
branes were not affected, and the general cell morphology did
not display any pronounced signs of apoptosis or necrosis.
Furthermore, the vacuoles were often empty, but membrane
structures could occasionally be found (Figure 6bv).
Immunoﬂuorescence staining showed altered distribution
of the ER chaperone calreticulin (Figure 6c). The ER formed
large vacuoles in WIN55,212-2-treated cells, conﬁrming
that the empty vacuoles within the cytoplasm are indeed
of ER origin.
Similar vacuoles, although smaller in size, were formed in
PB1primarycellstreatedwithWIN55,212-2(Figures7aiiiandiv)
compared with PB1 treated with vehicle (Figures 7ai and ii) for
24h.Thesmallersizeofthevacuolesinprimarycellsmightbe
Figure 3 Induction of LC3 II in Granta519 cells in response to WIN55,212-2. (a) Light microscopy images showing cellular morphology of Granta519 cells undergoing
cytoplasmic vacuolation after treatment with 10mM WIN55,212-2 for 48h (n¼3, one representative experiment is shown), digital magniﬁcation:  40. (b) WB for PARP,
LC3, p62 and b-actin in Granta519 cells treatedwith 10mM WIN55,212-2 or AEA or vehicle for 24 and 48h. Cell viability, measured by XTT assay (n¼3 3), of Granta519,
pretreated with (c)2 5mM CQ, (d) PD98059 or U0126 at indicated concentrations for 30min before WIN55,212-2 treatment
Figure 4 Effect of CB1 and CB2 antagonists on WIN55,212-2-induced cell
membrane integrity and LC3 II formation. (a) Granta519 cell were pretreated with
SR141716 (antagonist to CB1) and SR144528 (antagonist to CB2) for 30min
before incubation with increasing concentrations of WIN55,212-2 for 48h. Cell
viability was measured by PI uptake analyzed by ﬂow cytometry. (b) Western blot
shows LC3 I and LC3 II expression in Granta519 cells pretreated with SR141716
and /or SR144528 for 30min before 24h incubation with 10mM WIN55,212-2
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Cell Death and Diseasedue to the fact that lymphoma cells ex vivo do not proliferate
and the vacuolation process requires new protein synthesis.
XTT assay on PB1 cells treated with WIN55,212-2 for 48h did
not show any changes in mitochondrial activity upon
treatment (Figure 7b).
WIN55,212-2 induces ER stress in MCL. The morpho-
logical changes of ER in WIN55,212-2-treated Granta519
and PB1 cells prompted further investigation on expression
of ER stress-associated proteins: the ER chaperone
binding immunoglobulin protein (BiP) that binds to the
misfolded proteins and helps them to refold properly and
the transcription factor C/EBP (CCAAT/enhancer-binding
protein) homologous protein (CHOP) that participates in the
pro-apoptotic pathway of the unfolded protein response
(UPR). The analysis of BiP and CHOP by western blot
revealed that WIN55,212-2 treatment upregulates BiP and
CHOP proteins in all MCL cell lines studied up to 10h of
treatment with WIN55,212-2 (Figure 8a). This suggests that
WIN55,212-2 activates ER stress in MCL cells, but as this
response is similar in all investigated cell lines, the ER stress
does not discriminate between LC3-II-positive vacuolation
or apoptotic cell death. The levels of BiP and CHOP in
Granta519 cells remained high also after 24 and 48h of
treatment (Figure 8b).
Discussion
We have previously shown that exposure of MCL cells to
cannabinoids may induce PCD in vitro and tumor growth
reduction in an in vivo xenograft model of MCL. In most
instances, apoptosis is the mode of cell death. However, in
this report we show that other PCD mechanisms may also
induce cell death in MCLs, widening the potential therapeutic
usefulness of cannabinoids. The death pathway described in
this report was seen both in primary MCLs from two tissues
of one patient as well as in the MCL cell line Granta519. The
MCL cells that are resistant to cannabinoid-induced apoptotic
cell death die via cytoplasmic vacuolation upon cannabinoid
treatment. The similar formation of vacuoles, although more
pronounced in the Granta519 cell line compared with primary
MCLcells,indicatesthatthemechanism isnota phenomenon
of in vitro cultured cells alone, but may be relevant to primary
tumor cells.
Salazaretal.
25showedthatcannabinoids,apartfromPCDI
(apoptosis), can also induce PCD II (autophagy), followed by
caspase-3-dependent apoptosis in glioma, astrocytoma,
pancreatic cancer, breast cancer and hepatoma cells.
However the response in MCLs is different from that
described in Salazar et al.,
25 as we did not ﬁnd any convincing
evidence for autophagy. As Granta519 cells treated with
Figure 5 Washing off WIN55,212-2 or treatment with CHX protect Granta519 from WIN55,212-2-induced cytoplasmic vacuolation and cell death. (a) Cell viability of
Granta519andRec1cellsincubatedwith10mMWIN55,212-2for3and6hbeforewashingoffthedrug.Thencellswereincubatedfor48h,andcellviabilitywasmeasuredby
XTT (Po0.05). WB of Granta519 shows decreased LC3 lipidation by washing off 10mM WIN55,212-2 after 6h. (b) Cell viability (XTT) of Granta519 cells incubated
with 10mM WIN55,212-2 for 24h, followed by washing off the drug and reculturing for 24h (Po0.05). (c) CHX protects from WIN55,212-2-induced cell death measured by
XTT; *indicates statistical signiﬁcance (Po0.05)
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Cell Death and Diseasevehicle for 48h showed enhanced PARP cleavage com-
pared with cannabinoid-treated cells (Figure 3b), it could
be hypothesized that cannabinoids induced autophagy to
promote survival of starved cells, as all experiments were
performed in medium with low serum content. However, the
lack of enhanced autophagosome formation observed in TEM
micrographs and the lack of lysosomal contribution did not
conﬁrm this hypothesis.
Instead, the cannabinoid-induced vacuolation in Granta519
cells associated with decreased metabolism and formation
of LC3-II-positive non-autophagic vacuoles are similar to
previous descriptions in colon, breast and prostate cancer cell
lines treated with the prostaglandin derivative 15d-PGJ2.
21
These features resemble another type of PCD, called
paraptosis (from the Greek words para (alongside of,
abnormal) and apoptosis). It is characterized by the
appearance of large vacuoles of ER and mitochondrial
origin,
26 and has been denoted as PCD III. Paraptosis,
in contrast to apoptosis, does not show activation of the
caspase-3 cascade, followed by chromatin condensation nor
other apoptotic features.
27 Paraptosis has no speciﬁc deﬁni-
tion as yet, and several types of paraptosis-like cell deaths
have been described. The ﬁrst description of PCD by
cytoplasmic vacuolation, thus being a ‘golden standard’,
Figure 6 Granta519 cells form vacuoles in response to WIN55,212-2 treatment. (a) Light microscopy pictures of 0.5mm sections prepared as for TEM of Granta519 cells
treated with 10mM WIN55,212-2 or vehicle for 24h. Note the large cytoplasmic vacuoles. Occasional mitotic ﬁgures were also detected (black arrow); (b) TEM images of
Granta519 cells treated with 10mM WIN55,212-2. Photographs showed cells at different time points after 0 (i and ii); 2 (iii, iv); 6 (v and vi) and 24 (vii and viii)h of incubation.
Normal ultrastructure morphology was predominately found in the control cells (0h), showing a well-deﬁned plasma membrane and uniformly distributed chromatin in the
nucleus (i) and well-deﬁned organelles in the cytoplasm (ii). After 2h of WIN55,212-2 treatment, the cell cytoplasm displayed vacuoles with well-deﬁned membranes (arrows;
iii). Ribosomes(arrowheads) are attached to someof these membranes,indicatingthat thesevacuoles (*)were derivedfrom therough ER(iv). After6h, thenumber andsize
of these vacuoles increased and some contained membrane structures (arrows; v). The nuclear membrane was also affected, but the nuclear pore complexes were not
disrupted (arrows; vi). At 24h, more necrosis were found and the cells contained more vacuoles (vii). The vacuoles were mostly empty (*), and mitochondria were often found
in the cytoplasm (viii). Bars: i, iii, v and vii¼2mm; ii, iv, vi and viii¼1mm. (c) Fluorescence images of Granta519 cells incubated with vehicle or 10mM WIN55,212-2 for 24h
immunostained for calreticulin (green) and DAPI (blue). White arrows indicate vacuoles surrounded by calreticulin
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Cell Death and Diseasewas triggered by the overexpression of insulin-like growth
factor-1 receptor (IGF1R) in 293T, HEK293, MCF-7 and
Cos-7 cells.
26 Since then the list of cytoplasmic vacuolation
inducers has been accumulating, allowing the description of
and distinguishing different types of paraptosis-like cell death.
For example, epidermal growth factor (EGF)-induced para-
ptosis differs by induction of simultaneous caspase-indepen-
dent DNA fragmentation.
28 IGF1R-induced paraptosis
showed to be mediated by the MAPK cascade and sensitive
to the MEK-2 inhibitor U0126.
24 15d-PGJ2-induced
paraptosis is mediated by both the MEK-1 and -2 cascades.
21
We investigated whether the cannabinoid-induced
vacuolation in Granta519 was inhibited by MEK-1 and -2
inhibitors. Similarly to the taxol-induced vacuolation in the
ASTC lung adenocarcinoma cell line and the EGF-induced
vacuolation in the GH4C1 rat somatolactotrope cell line, the
MEK-2 inhibitor U0126 did not block cannabinoid-induced cell
Figure 7 WIN55,212-2 induced vacuolation in PB1 cells. (a) Normal
ultrastructure morphology of primary PB1 cells was predominately found in cells
treated with the vehicle for 24h. These cells had a well-deﬁned plasma membrane
anduniformlydistributedchromatininthenucleusandwell-deﬁnedorganellesinthe
cytoplasm (i and ii). Cells treated with WIN55,212-2 for 24h displayed vacuoles
in the cytoplasm. Bars; i and iii¼2mm; ii and iv¼1mm. (b) PB1 cell viability (XTT)
in response to WIN55,212-2 for 48h. The experiment was performed once in
triplicates
Figure 8 Expression of ER stress markers in MCL cell lines treated with 10mM
WIN55,212-2. (a) Western blots depicting expression levels of proteins, BiP, CHOP
and b-actin, in Granta519, Rec1, JeKo and JVM2 cell lines treated with 10mM
WIN55,212-2inatime-courseexperiment.(b)ExpressionofBiP,CHOPandactinin
Granta519 cells treated with 10mM WIN55,212-2 or vehicle for 24 and 48 h
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Cell Death and Diseasedeath in Granta519. Furthermore, even though both canna-
binoids and taxol induce vacuolation of ER origin, the
cannabinoid-induced vacuolation, in contrast to the taxol-
induced vacuolation,
29,30 requires active protein synthesis.
This is similar to CHX-sensitive vacuolation induced by
IGF1R
26 and 15d-PGJ2.
21 Although the cannabinoid-induced
vacuolation has many features in common with other
paraptosis-like types of cell death, there are also features
that are different from paraptosis induced by prostaglandin
derivatives, IGF1R overexpression and taxol.
Previously, we have shown that caspase-3 activation in
MCL cell lines treated with cannabinoids can be inhibited by
cell treatment with selective CB1 and CB2 antagonists,
SR141716 and SR144528, respectively. Here, we show that
neither of these antagonists inhibits WIN55,212-2-induced
celldeathorLC3IIformationinGranta519.This suggeststhat
the paraptotic cell death occurs independent of cannabinoid
receptor signaling. Similar ﬁndings have been reported
in studies on the prostaglandin derivative, 15d-PGJ2, that
activates paraptosis independent of its target receptor,
peroxisomeproliferator-activatedreceptor-g.
21Wealsoreport
that WIN55,212-2-induced cell death of Granta519 and Rec1,
representing cell lines undergoing paraptosis and apoptosis,
respectively, needs constant presence of the cell death
stimulus to complete the cell death program. This suggests
that cannabinoid-induced cell death may be ﬁnely tuned and
controlled by repetitive administration of the drug.
TEM and immunoﬂuorescence staining of calreticulin
suggest that the vacuoles observed in Granta519 and
PB cells treated with WIN55,212-2 are of ER origin. We also
observe changes in morphology of mitochondria. These
changes occur later (6–12h post treatment) than vacuoles
andprobably are a secondaryeffect,ascellsbythis time point
show a dramatic change in the morphology.
Cannabinoids can signal for cell death in various types
of cancer cells, including MCL, via ceramide de novo
synthesis
18,20,31 occurring in the ER.
32 Both pharmacological
and genetic inhibition of the key enzymes participating in
biosynthesisofceramideabrogatedcelldeathofcannabinoid-
treated Rec1 cells.
33 Accumulation of newly synthesized
ceramides in ER can cause ER stress, as reported by Salazar
et al.
25 in THC-treated glioma cells. We now show that the
levels of the ER stress proteins, BiP and CHOP, increase in
MCL cell lines during 10h of incubation with WIN55,212-2.
In Granta519, BiP and CHOP remain elevated at 24 and 48h,
respectively, thus at a time point when the process of LC3-II-
positive cytoplasmic vacuolation is extensive. This is in line
with other reports showing that cannabinoids activate ER
stress.
25,34 Importantly, ER stress has been also associated
with the paraptotic cell death.
21,35 The fact that cannabinoids
induceERstressinallMCLcelllinesstudiedsuggeststhatthe
cell decision on entering apoptotic or paraptotic signaling
pathway happen after or independent of pro-death UPR
signaling. Extensive ER dilation can relate to malfunctioning
downstream of apoptotic pathways due to drug effects or
genetic alterations in cancer cells. Tardito et al. showed that
the copper complex A0
35 and other copper complexes,
36 as
well as activating UPR, inhibit caspase-3, probably by direct
interactions of copper with the catalytic cysteine in the active
site of caspase-3. Moreover, Ding et al.
37 proposed that
proteasome inhibitor MG132 leads to post-UPR ER dilation in
Bcl2-associated X protein (Bax)-negative as opposed to
Bax-positive HCT116 cells.
The molecular bases for these different PCD responses to
cannabinoids are yet unknown. Possibly, the balances
between pro- and anti-apoptotic factors, such as B-cell
lymphoma 2 (Bcl2) family molecules, are divergent between
MCLs that are sensitive to cannabinoid-inducing apoptosis
and those that undergo paraptosis. Overexpression of BCL2
is not an uncommon event in malignant lymphomas, including
MCL, and may be a result of genomic aberrations encom-
passing the BCL2 locus at chromosome 18q21. In contrast
to Rec1, Granta519 carries increased copy numbers of BCL2
and expresses higher BCL2 mRNA levels.
38 We cannot
exclude the possibility that increased expression of BCL2
contributed to the resistance to cannabinoid-induced apopto-
sis in Granta519. However, JeKo has a near-triploid karyo-
type, and CGH analysis has demonstrated an extra copy
of BCL2 in this cell line.
39 Furthermore, Sperandio et al.
26
showed that, among other inhibitors of apoptosis, a pro-
survival member of Bcl2 family, B-cell lymphoma-extra large
(Bcl-xL), did not protect 293T-IGFR-IC cells from paraptotic
cell death, indicating that proteins outside of anti-apoptotic
Bcl2 family members may be of greater importance. Chen
et al.
40 recently showed that Granta519 cells respond
differently to an inhibitor of cyclin-dependent kinases 2, 7
and9,SNS-032, than otherMCLcell linestested.Theauthors
speculated that Epstein–Barr virus (EBV) positivity as well as
Bcl2 overexpression could contribute to the altered response
of Granta519 cell line to SNS-032.
40 However, the EBV-
positiveJVM2celllineunderwentapoptosiswhentreatedwith
cannabinoids. Furthermore, the primary MCL cells from
patient PB were EBER (EBV-encoded RNA) negative (data
not shown).
We conclude that cannabinoids may induce cell death by a
pathway associated with cytoplasmic vacuolation in cases
of MCLs that are resistant to apoptosis. Activation of more
than one type of cell death by cannabinoids widens their
potential therapeutic usefulness toward lymphomas over-
expressing cannabinoid receptors.
Materials and Methods
Reagents. WIN55,212-2 and AEA were from Tocris (Bristol, UK). CQ, CHX and
PI were from Sigma-Aldrich (Dorset, UK). PD98059 and U0126 were from
Calbiochem (Merck, Darmstadt, Germany). SR141716 and SR144528 were from
Cayman Chemical (Ann Arbor, MI, USA).
Patient samples. Tumour cells were isolated as described previously,
20
viability frozen in freezing medium containing 10% DMSO (Merck, Darmstadt,
Germany), 40% fetal bovine serum (FBS; Invitrogen, Paisley, UK) and 50%
RPMIþGlutaMax (Invitrogen) according to the Biobank procedures at Karolinska
University Hospital, Huddinge, and stored at  1351C
Cell culture of primary cells and cell lines. Granta519, Rec1, JeKo,
JVM2 cell lines and primary cells were obtained and cultured as previously
described.
4 Beforesettingup experiments,cellswerecultured for 4h (primarycells)
or overnight (cell lines) in RPMIþGlutaMax (Invitrogen) with 1% FBS (Invitrogen).
It is common to use 1% serum in media when performing experiments with
cannabinoids, as many cannabinoids bind to serum components (for a review,
see Flygare and Sander
18).
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(primarily) mitochondrial, metabolic activity) according to the manufacturer’s
instructions (Roche, Mannheim, Germany) or by (2) ﬂow cytometric analysis
(FACSCalibur, BD Biosciences, Bedford, MA, USA) of PI (Sigma-Aldrich; ﬁnal
concentration 1mg/ml) uptake by cells lacking plasma membrane integrity. Results
were analyzed using FlowJo 7 (Tree Star Inc., Ashland, OR, USA) for Windows, and
pharmacological interpretation was done using a four-parameter logistic equation with
iterative ﬁtting (dose–response ﬁtting) using OriginPro 8 (OriginLab, Northampton, MA,
USA).
Western blotting. Cells were pelleted and frozen at  201C or used
immediately after pelleting for preparing cell lysates using RIPA buffer (Sigma-
Aldrich) supplemented with protease inhibitor cocktail (Sigma-Aldrich). Proteins
were separated on 12% NuPAGE gels from Invitrogen and then transferred using
semidry transfer system onto PVDF membrane (Millipore, Solna, Sweden).
Membranes were blocked with 10% dry milk in TBS solution for 2h at room
temperature (RT) and then probed overnight at 41C or for 2h at RT with primary
antibodies: anti-PARP, anti-caspase-3, anti-LC3, anti-BiP or anti-Akt (Cell
Signaling, Danvers, MA, USA) or anti-p62, anti-b-actin (Sigma-Aldrich) in 5% dry
milk or 5% BSA for anti-CHOP (Cell Signaling) in TBS. Membranes were then
washed in TBS and probed with secondary antibodies (anti-rabbit or anti-mouse;
GE Healthcare Bio-Sciences Corp., Uppsala, Sweden). Blots were developed
using Supersignal West Pico (Pierce, Biotechnology, Shelton, CT, USA) and
wet-developing method (developer and ﬁxer solutions were from Kodak (Sigma-
Aldrich) and ﬁlms were from GE Healthcare). For reprobing membranes, HRP was
blocked using the SG substrate kit (Vector Labs, Peterborough, UK).
RNA isolation and cDNA synthesis. RNA was isolated using the RNeasy
Plus mini kit (Qiagen, Sollentuna, Sweden) according to the manufacturer’s
protocol. Quantiﬁcation and quality of the RNA preparations were measured using
the NanoDrop ND-1000 spectrophotometer (Saveen Werner, Stockholm, Sweden).
Complementary DNA (cDNA) was synthesized using the Omniscript Reverse
Transcription kit (Qiagen) according to manufacturer’s protocol. RNaseOut
recombinant ribonuclease inhibitor and the oligo dT primers used were
purchased from Invitrogen.
Quantitative PCR. mRNA expression levels of CNR1 and CNR2 were
assessed by real-time PCR using Platinum SYBR Green qPCR Supermix-UDG
(Invitrogen) according to the manufacturer’s protocol. Primers sequences
(Eurogentec, Seraing, Belgium) for the selected genes were as follows: CNR1
forward: 50-CATTAAGACGGTGTTTGCATTCT-30 and reverse: 50-CGTGTCG
CAGGTCCTTACTC-30, amplifying 1185–1282bp (transcript variant 1) and 1018–
1115bp (transcript variant 2). CNR2 primers were 50-GACACGGACCC
CTTTTTGCT-30 (forward primer) and 50-CCTCGTGGCCCTACCTATCC-30
(reverse primer), amplifying 1321–1423bp. b-Actin primers were 50-AAAGACCT
GTACGCCAACACA-30 (forward primer) and 50-AGTACTTGCGCTCAGGAGGA-30
(reverse primer), amplifying 955–1096bp. Each sample was prepared in triplicates
in a 96-well plate (Bio-Rad Laboratories, Sundyberg, Sweden) and the reactions
were performed with the C1000 Thermal cycler (Bio-Rad). An initial step was
performed at 951C for 2min, followedby 40 cycles at 951C for 15s and ﬁnished by
571C for 30s. The results were analyzed and cycle threshold (Ct) values of
transcriptswerequantiﬁedusingCFXmanagersoftware(Bio-Rad).TheDCt values
were calculated using b-actin as reference. cDNA from buffy coat B cells was used
as control for CNR1 and CNR2 to calculate the DDCt value and to determine the
relative fold increase.
Immunoﬂuorescence microscopy. Cells were grown on poly-L-lysine-
coatedcoverslips,thenspundown,washedandincubatedwith4%PFAatRT.After
washing, cells were incubated with primary mouse anti-calreticulin (Abcam,
Cambridge, UK) antibody at 41C overnight. After washing secondary anti-mouse,
Alexa488-conjugated antibody was applied for 1h at RT. Cells were washed and
mounted onto slide using mounting media with DAPI (Vector Labs). Staining was
examined on Leica DM RXA ﬂuorescence microscope (Leica Microsystems,
Wetzlar, Germany) using SlideBook 5.0 software (Intelligent Imaging Innovations,
Go ¨ttingen, Germany). The images were analyzed using software ImageJ for
Macintosh (US National Institutes of Health, Bethesda, MD, USA).
Transmission electron microscopy. Cells were ﬁxed in 2.5%
glutaraldehyde in 0.1M phosphate buffer, pH 7.4, at RT for 30min. Next, cells
were transferred to Eppendorf tubes (Hamburg, Germany) and further ﬁxed
overnight in the refrigerator. After ﬁxation, cells were rinsed in 0.1M phosphate
buffer and centrifuged. The pellets were then postﬁxed in 2% osmium tetroxide in
0.1M phosphate buffer, pH 7.4, at 41C for 2h, dehydrated in ethanol, followed by
acetone and embedded in LX-112 (Ladd, Burlington, VT, USA). Sections were
contrasted withuranylacetate,followedbyleadcitrateandexaminedinaTecnai12
TEM (Fei Company, Eindhoven, The Netherlands) at 80kV. Digital images were
taken by using a Veleta camera (Olympus Soft Imaging Solutions, GmbH, Munster,
Germany).
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